EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1], today announced the listing of Safe Orthopaedics, a French medical technology company, in Compartment C of the Euronext Paris regulated market.
Founded in 2010, Safe Orthopaedics develops and markets an innovative range of sterile implants and associated single-use surgical instruments, designed to optimise spinal surgery and make it safer and less costly. By eliminating the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome, unreliable logistics of instrument sterilisation, and limits hospital costs.
Safe Orthopaedics (ticker code: SAFOR) was listed through the admission to trading of the 12,937,903 ordinaryshares making up its equity, including 3,750,641new shares issued under a Global Offering[2].
The admission and issue price of Safe Orthopaedics shares was set at €2.55 per share. Market capitalisation was €33 million on the day of listing, and the transaction raised a total of €9.6 million.
Yves Vignancour, CEO of Safe Orthopaedics said: “Our listing on Euronext is a key stage in stepping up the pace of our product innovation and international growth. We would like to thank our existing shareholders, as well as all those who have joined us now, for their trust and support in making spinal surgery safer and more effective.”
Eric Forest, Chairman and CEO of EnterNext said: “We congratulate Safe Orthopaedics, an innovative spinal surgery specialist, on its listing on Euronext—a move that brings it into the dynamic 66-member family of life science businesses listed on Euronext markets. This operation will enable the company to support and accelerate deployment of its innovative and ambitious strategy on global markets.”
[1]Small and medium-size companies
[2]The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries
